Awakn Life Sciences Corp. Receives U.K. MHRA’s Innovative Licensing for its Breakthrough Therapy for Severe Alcohol Use Disorder
Awakn Life Sciences Corp., a biotechnology company specializing in developing addiction therapies with a primary focus on Alcohol Use Disorder (AUD), announces that U.K. MHRA has granted Innovation Pa ...
FDA Grants Orphan Drug Designation to Ezurpimtrostat (GNS561) for Hepatocellular Carcinoma (HCC) Treatment
Genoscience Pharma today announces that its lead candidate, ezurpimtrostat (GNS561), a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, has been granted Orphan Drug Designation by the U.S. FDA for ...